CD274 and neoplasm: Furthermore, we have reported that no significant changes were seen in parameters such as the activity of T cells, PD-L1 expression, or myeloid/phagocytic cell markers in a nivolumab phase II clinical trial in patients with GBM treated with nivolumab through a comprehensive immunobiological comparative study between pre- and post-treatment tumor biopsies in respect to controls [8].